Genmab (Otc) ( (GMAB) ) has released its Q1 earnings. Here is a breakdown of the information Genmab (Otc) presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genmab, a biotechnology company based in Denmark, specializes in the development of antibody therapeutics for cancer treatment, leveraging its proprietary technology platforms. In its latest earnings report, Genmab announced significant progress in its product pipeline, including the approval of EPKINLY for follicular lymphoma in Japan and Tivdak for cervical cancer in both Japan and the European Union. The company’s revenue for the first quarter of 2025 increased by 19% to $715 million, driven by higher royalties from DARZALEX and Kesimpta, as well as EPKINLY sales. Operating profit rose to $188 million, reflecting the company’s strategic focus on expanding its product reach and pipeline development. Looking ahead, Genmab maintains its financial guidance for 2025, anticipating continued growth through its collaborations and product innovations.